Late Clinical Development of KH176: an innovative orphan drug to reach mitochondrial disease patients & market

Project Information

KHON2bTREAT

Grant agreement ID: 830115

DOI

10.3030/830115

Project closed

EC signature date 26 September 2018

Start date 1 October 2018

End date 30 June 2022

Funded under

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Total cost

€ 3 337 525,00

EU contribution

€ 2 336 267,50

Coordinated by

KHONDRION BV
Netherlands

CORDIS provides links to public deliverables and publications of HORIZON projects.

Links to deliverables and publications from FP7 projects, as well as links to some specific result types such as dataset and software, are dynamically retrieved from OpenAIRE .

Deliverables

Websites, patent fillings, videos etc. (2)

Dissemination material
Press releases and information papers on KHON2bTREAT to relevant stakeholders

Publications

Non-peer reviewed articles (1)

Sonlicromanol improves neuronal network dysfunction and transcriptome changes linked to m.3243A>G heteroplasmy in iPSC-derived neurons

Author(s): Teun M. Klein Gunnewiek Anouk H.A. Verboven Iris Pelgrim Mark Hogeweg Chantal Schoenmaker Herma Renkema Julien Beyrath Jan Smeitink Bert B.A. de Vries Peter-Bram A.C. ’t Hoen Tamas Kozicz Nael Nadif Kasri
Published in: ISSCR, Issue Volume 16, Issue 9, 2021, Page(s) 2197-2212, ISSN 0020-0255
Publisher: Elsevier BV
DOI: 10.1016/j.stemcr.2021.07.002

Intellectual Property Rights

Patent (1)

CHROMANYL DERIVATIVES FOR TREATING MITOCHONDRIAL DISEASE

Application/Publication number: 13 759838
Date: 2013-07-12
Applicant(s): KHONDRION BV